Skip to content

Author

Jaco Botha

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety, Efficacy, and Pharmacokinetics of Agalsidase Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase 3, Open-Label, Single-Arm Study.

Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease and safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations.

Hong Ren, Jian-Hua Mao, Rong Wang et al. · 0 citations
Review Oct 2026

Clinical characteristics and management of patients with mucopolysaccharidosis II in the United States enrolled in the Hunter Outcome Survey.

BACKGROUND In 2022, mucopolysaccharidosis II (MPS II) was added to the list of disorders recommended for inclusion in newborn screening panels in the USA; this is expected to substantially facilitate earlier diagnosis and treatment and improve patient outcomes. An analysis was conducted in US patients enrolled in the H...

Barbara K. Burton, C. Ficicioglu, Helio F. Pedro et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.